-
公开(公告)号：US20070049579A1
公开(公告)日：2007-03-01
申请号：US11366454
申请日：2006-03-03
申请人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
发明人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
IPC分类号： A61K31/551
CPC分类号： A61K31/551
摘要： A medicament having a neovascularization promoting action, which comprises a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid as an active ingredient and is useful for prophylactic and/or therapeutic treatment of ischemic diseases and wounds.
摘要翻译： 具有新血管形成促进作用的药物，其包含类视黄醇拮抗剂，例如4-（5H-7,8,9,10-四氢-5,7,7,10,10-五甲基苯并[e]萘并[2,3- b] [1,4]二氮杂萘-13-基）苯甲酸作为活性成分，可用于预防和/或治疗缺血性疾病和伤口。
-
公开(公告)号：US20050234130A1
公开(公告)日：2005-10-20
申请号：US10511274
申请日：2003-04-22
IPC分类号： A61K31/27 , A61K31/695 , A61L31/16 , A61P9/00 , A61P9/10 , A61P9/14 , A61P43/00 , A61K31/195 , A61K31/203
CPC分类号： A61K31/27 , A61K31/695 , A61L31/16
摘要： A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[(3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.
摘要翻译： 用于使用血管内支架的经皮腔内冠状动脉成形术之后的血管疾病如血管再狭窄和/或再闭塞的预防和/或治疗性治疗药物，其包含选自维甲酸类和控制剂的活性成分 类维生素如4- [5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基）氨基甲酰基]苯甲酸或其盐或4 - [[[（3,3- （三甲基甲硅烷基）苯基]羰基]氨基]苯甲酸或其盐，其中所述物质对血管内皮细胞基本上没有抗增殖作用，但对血管平滑肌细胞基本具有抗增殖作用。
-
公开(公告)号：US20090118264A1
公开(公告)日：2009-05-07
申请号：US12318248
申请日：2008-12-23
申请人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
发明人： Ryozo Nagai , Ichiro Manabe , Takayuki Shindo , Hiroshi Iwata , Koichi Shudo , Hiroyuki Kagechika
IPC分类号： A61K31/551 , A61K31/4164 , A61K31/39 , A61K31/4439 , A61P9/10
CPC分类号： A61K31/551
摘要： Methods of use of medicaments having neovascularization promoting action, which medicaments comprise a retinoid antagonist such as 4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo[e]naphtho[2,3-b][1-,4]diazepin-13-yl)benzoic acid as an active ingredient.
摘要翻译： 使用具有新血管形成促进作用的药物的方法，该药物包含类视黄醇拮抗剂如4-（5H-7,8,9,10-四氢-5,7,7,10,10-五甲基苯并[e]萘并[2 ，3-b] [1-，4]二氮杂-13-基）苯甲酸作为活性成分。
-
公开(公告)号：US20130304184A1
公开(公告)日：2013-11-14
申请号：US13988870
申请日：2011-11-25
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61L31/022 , C22C38/001 , C22C38/002 , C22C38/02 , C22C38/04 , C22C38/06 , C22C38/22 , C22C38/26 , C22C38/28 , C22C38/32 , C22C38/44
摘要： A nickel-free stainless steel stent using a stainless steel which does not substantially contain Ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of Cr, from 0.97 to 2% by mass of Mo, and from 0.5 to 1% by mass of N, with the remainder being Fe, and optionally containing inevitable impurities.
摘要翻译： 使用不锈钢不含镍的不含镍的不锈钢支架，具有金属过敏起效防止效果，并且在精加工性，强度和延展性方面优异。 无镍不锈钢支架的特征在于，使用含有15〜30质量％的Cr，0.97〜2质量％的Mo和0.5〜1质量％的作为化学组成的不锈钢， N，其余为Fe，并且任选地含有不可避免的杂质。
-
公开(公告)号：US20130045277A1
公开(公告)日：2013-02-21
申请号：US13576718
申请日：2011-02-01
CPC分类号： A61L31/10 , A61L31/16 , A61L2300/602
摘要： Disclosed is a biocompatible device surface-coated on the base material thereof with a biocompatible polymer layer having antithrombogenicity and endothelialization activity, and embedded in or attached to a living body for use. The polymer layer comprises a polymer matrix formed by the crosslinking of a cell-adhesive peptide-containing polymer.
摘要翻译： 公开了一种在其基材上表面涂覆有生物相容性聚合物层的生物相容性装置，其具有抗血栓形成和内皮化活性，并且嵌入或附着于生物体使用。 聚合物层包含通过含细胞粘着肽的聚合物交联而形成的聚合物基质。
-
公开(公告)号：US20070275917A1
公开(公告)日：2007-11-29
申请号：US10565997
申请日：2004-07-29
申请人： Ryozo Nagai , Ichiro Manabe , Atsushi Ishihara , Tsuneaki Tottori
发明人： Ryozo Nagai , Ichiro Manabe , Atsushi Ishihara , Tsuneaki Tottori
CPC分类号： C12N15/113 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14
摘要： An RNA capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence, and which has been designed from the nucleotide sequence of Kruppel-like factor 5 (KLF5) cDNA. Specifically, a double-stranded RNA having a strand of a sequence shown in any one of SEQ ID NOS: 2 to 16 and a strand of a sequence complementary to the sequence, in which 2 uridylic acids are added to the 3′-terminus of each of the strands. By transfecting the RNA or a vector for expression of the RNA into cells, the expression of KLF5 gene in the cells can be suppressed. The RNA or a vector for expression of the RNA can be used as a therapeutic agent for cardiovascular disease or cancer.
摘要翻译： 能够抑制KLF5基因表达的RNA，其包含由KLF5 mRNA的15〜30个连续核苷酸和与该序列互补的序列组成的序列，并且由Kruppel样因子5（KLF5）的核苷酸序列设计 ）cDNA。 具体地说，具有SEQ ID NO：2〜16中任一项所示的序列的链的双链RNA和与该序列互补的序列的链，其中2个尿苷酸加入到 每个股。 通过将RNA或用于将RNA表达的载体转染到细胞中，可以抑制细胞中KLF5基因的表达。 用于表达RNA的RNA或载体可用作心血管疾病或癌症的治疗剂。
-
公开(公告)号：US20130210860A1
公开(公告)日：2013-08-15
申请号：US13878136
申请日：2011-10-05
申请人： Ichiro Manabe , Ryozo Nagai , Fusa Ogata
发明人： Ichiro Manabe , Ryozo Nagai , Fusa Ogata
CPC分类号： A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/44 , A61K31/47 , A61K31/505
摘要： Provided is a new prophylactic and/or therapeutic agent for lymphedema, for which until now there has been no effective means of treatment, and the prophylactic and/or therapeutic agent for lymphedema comprises, as an active ingredient, a compound represented by the following formula (1), a lactone derivative thereof, or a salt of the compound or lactone derivative: wherein R1 represents an organic group, X represents —CH2CH2— or —CH=CH—, and R2 represents a hydrogen atom or an alkyl group.
摘要翻译： 提供了一种用于淋巴水肿的新的预防和/或治疗剂，迄今为止没有有效的治疗方法，并且用于淋巴水肿的预防和/或治疗剂包含作为活性成分的由下式表示的化合物 （1）表示的化合物或其内酯衍生物或化合物或内酯衍生物的盐：其中R1表示有机基团，X表示-CH2CH2-或-CH = CH-，R2表示氢原子或烷基。
-
8.发明申请Composition Suppressing The Expression of Target Gene in Eyeball and Medicament For Treating of Disease in Eyeball 审中-公开抑制眼球中靶基因表达和治疗眼球疾病药物的组合物公开(公告)号：US20090175930A1
公开(公告)日：2009-07-09
申请号：US12087674
申请日：2007-01-10
申请人： Nobuhiro Yagi , Masahiro Yamauchi , Noboru Aoki , Yasuhiro Tamaki , Hidenori Takahashi , Aya Iriyama , Ryozo Nagai , Ichiro Manabe
发明人： Nobuhiro Yagi , Masahiro Yamauchi , Noboru Aoki , Yasuhiro Tamaki , Hidenori Takahashi , Aya Iriyama , Ryozo Nagai , Ichiro Manabe
IPC分类号： A61K9/127 , A61K31/7052 , A61P27/02
CPC分类号： A61K9/1272 , A61K9/0048 , A61K9/127 , A61K31/7105 , A61K48/0033 , A61K48/0041 , C12N15/111 , C12N2310/14 , C12N2320/32
摘要： There is provided a composition comprising an RNA-encapsulated liposome, the RNA comprising a sequence being of 15 to 30 contiguous nucleotides of mRNA of a target gene associated with a disease in an eyeball, and a sequence complementary to the sequence, wherein the liposome is capable of reaching an eyeball, and the like. The liposome in which an RNA is encapsulated is, for example, a liposome composing a complex particle comprising a lead particle and the RNA as constituent components, the lead particle comprising a cationic lipid, and a bilayer lipid membrane for coating the complex particle. The bilayer lipid membrane is a bilayer lipid membrane comprising a neutral lipid, and a lipid derivative, a fatty acid derivative or an aliphatic hydrocarbon derivative of a water-soluble substance as constituent components.
摘要翻译： 提供了包含RNA包封的脂质体的组合物，所述RNA包含与眼球中的疾病相关的靶基因的mRNA的15-30个连续核苷酸的序列和与该序列互补的序列，其中所述脂质体是 能够达到眼球等。 其中包封RNA的脂质体是例如构成包含铅颗粒和RNA作为组成成分的复合颗粒的脂质体，包含阳离子脂质的铅颗粒和用于涂覆复合颗粒的双层脂质膜。 双层脂质膜是包含中性脂质和作为组成成分的水溶性物质的脂质衍生物，脂肪酸衍生物或脂肪族烃衍生物的双层脂质膜。
-
公开(公告)号：US09320622B2
公开(公告)日：2016-04-26
申请号：US13988870
申请日：2011-11-25
IPC分类号： C22C38/22 , C22C38/02 , C22C38/04 , A61F2/82 , C22C38/00 , C22C38/26 , C22C38/28 , A61L31/02
CPC分类号： A61F2/82 , A61L31/022 , C22C38/001 , C22C38/002 , C22C38/02 , C22C38/04 , C22C38/06 , C22C38/22 , C22C38/26 , C22C38/28 , C22C38/32 , C22C38/44
摘要： A nickel-free stainless steel stent using a stainless steel which does not substantially contain Ni in the stainless steel, has a metal allergy onset-preventing effect, and is excellent in terms of precision workability, strength, and ductility, is provided. The nickel-free stainless steel stent is characterized by using a stainless steel containing, as a chemical composition, from 15 to 30% by mass of Cr, from 0.97 to 2% by mass of Mo, and from 0.5 to 1% by mass of N, with the remainder being Fe, and optionally containing inevitable impurities.
摘要翻译： 使用不锈钢不含镍的不含镍的不锈钢支架，具有金属过敏起效防止效果，并且在精加工性，强度和延展性方面优异。 无镍不锈钢支架的特征在于，使用含有15〜30质量％的Cr，0.97〜2质量％的Mo和0.5〜1质量％的作为化学组成的不锈钢， N，其余为Fe，并且任选地含有不可避免的杂质。
-
公开(公告)号：US07850976B2
公开(公告)日：2010-12-14
申请号：US12041279
申请日：2008-03-03
申请人： Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motoo Tomita
发明人： Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motoo Tomita
CPC分类号： A61K38/2264
摘要： The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).
摘要翻译： 本发明提供胰岛素抵抗改善剂和2型糖尿病治疗剂，其含有脂联素的C末端球状结构域，脂联素或结合域或脂联素的基因。 本发明还提供了一种通过施用上述药物来改善胰岛素抵抗和治疗2型糖尿病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.023 秒)
